EA200970700A1 - Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний - Google Patents
Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеванийInfo
- Publication number
- EA200970700A1 EA200970700A1 EA200970700A EA200970700A EA200970700A1 EA 200970700 A1 EA200970700 A1 EA 200970700A1 EA 200970700 A EA200970700 A EA 200970700A EA 200970700 A EA200970700 A EA 200970700A EA 200970700 A1 EA200970700 A1 EA 200970700A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cancer
- diseases
- fusion proteins
- diseases caused
- kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Соединения в соответствии с данным изобретением находят применение в лечении рака млекопитающих, особенно рака человека, включающего, но не ограниченного ими, злокачественные меланомы, солидные опухоли, глиобластомы, рак яичников, рак поджелудочной железы, рак простаты, раки легких, раки молочной железы, раки почек, печеночные раки, карциномы шейки матки, метастазы первичных мест опухоли, миелопролиферативные заболевания, хронический миелогенный лейкоз, папиллярную карциному щитовидной железы, немелкоклеточный рак легких, мезотелиому, гиперэозинофильный синдром, желудочно-кишечные стромальные опухоли, раки прямой кишки, глазные заболевания, характеризуемые гиперпролиферацией, ведущей к слепоте, включая различные ретинопатии, диабетическую ретинопатию, ревматоидный артрит, астму, хроническое обструктивное заболевание легких, мастоцитоз, лейкоз мастоцитов, заболевания, вызываемые с-Abl киназой, ее онкогенными формами, ее аберрантными слитыми белками и ее полиморфами, заболевания, вызываемые c-Kit киназой, ее онкогенными формами, ее аберрантными слитыми белками и ее полиморфами, заболевания, вызываемые c-Met киназой, ее онкогенными формами, ее аберрантными слитыми белками и ее полиморфами, или заболевания, вызываемые Raf киназой, ее онкогенными формами, ее аберрантными слитыми белками и ее полиморфами.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91321607P | 2007-04-20 | 2007-04-20 | |
PCT/US2008/060896 WO2008131276A1 (en) | 2007-04-20 | 2008-04-18 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200970700A1 true EA200970700A1 (ru) | 2010-02-26 |
Family
ID=39872877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200970700A EA200970700A1 (ru) | 2007-04-20 | 2008-04-18 | Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний |
Country Status (14)
Country | Link |
---|---|
US (4) | US8143293B2 (ru) |
EP (5) | EP2148677A4 (ru) |
JP (2) | JP2010524974A (ru) |
KR (2) | KR20100014811A (ru) |
CN (2) | CN101878031A (ru) |
AU (4) | AU2008251723A1 (ru) |
BR (2) | BRPI0807717A2 (ru) |
CA (4) | CA2684949A1 (ru) |
EA (1) | EA200970700A1 (ru) |
IL (1) | IL201650A0 (ru) |
MX (2) | MX2009009066A (ru) |
RU (1) | RU2009142851A (ru) |
SG (1) | SG183054A1 (ru) |
WO (4) | WO2008131227A1 (ru) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101878031A (zh) | 2007-04-20 | 2010-11-03 | 迪赛孚尔制药有限公司 | 用于治疗骨髓增生性疾病和其他增生性疾病的激酶抑制剂 |
US20110189167A1 (en) * | 2007-04-20 | 2011-08-04 | Flynn Daniel L | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases |
EA201170627A1 (ru) * | 2008-10-29 | 2011-10-31 | ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Циклопропанамиды и аналоги, проявляющие противораковые и антипролиферативные активности |
EP2473513B1 (en) * | 2009-09-03 | 2019-06-05 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
US8609663B2 (en) * | 2009-11-18 | 2013-12-17 | University Of Massachusetts | Compounds for modulating TLR2 |
ES2575215T3 (es) | 2009-12-11 | 2016-06-27 | Autifony Therapeutics Limited | Derivados de imidazolidindiona |
US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
KR20130091331A (ko) * | 2010-07-16 | 2013-08-16 | 교와 핫꼬 기린 가부시키가이샤 | 함질소 방향족 복소환 유도체 |
CN103080109A (zh) * | 2010-09-01 | 2013-05-01 | 苏州爱斯鹏药物研发有限责任公司 | 氘代杂环化合物激酶抑制剂 |
CN102408408A (zh) * | 2010-09-20 | 2012-04-11 | 北大方正集团有限公司 | 具有抗肿瘤作用的芳基脲衍生物 |
CN102432592A (zh) * | 2010-09-29 | 2012-05-02 | 北大方正集团有限公司 | 具有抗肿瘤作用的芳基脲衍生物及其制备方法 |
BR112013013914B1 (pt) | 2010-12-06 | 2021-10-26 | Autifony Therapeutics Limited | Compostos derivados de hidantoína úteis como inibidores de kv3, usos dos referidos compostos e composição farmacêutica compreendendo os mesmos |
US8563558B2 (en) * | 2010-12-06 | 2013-10-22 | Confluence Life Sciences, Inc. | Substituted pyridine urea compounds |
CN102558144A (zh) * | 2010-12-22 | 2012-07-11 | 北大方正集团有限公司 | 一种芳基脲衍生物 |
CN102532113B (zh) * | 2010-12-22 | 2014-09-10 | 北大方正集团有限公司 | 芳基脲衍生物 |
KR20120100027A (ko) * | 2011-03-02 | 2012-09-12 | 한국생명공학연구원 | 엔도사이토시스 모티프 및 단백질 도입 도메인을 포함하는 암 예방 또는 치료용 약학적 조성물 |
CN103649076B (zh) | 2011-05-13 | 2015-09-09 | 阵列生物制药公司 | 作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物 |
CN103596943B (zh) | 2011-06-07 | 2016-10-12 | 奥蒂福尼疗法有限公司 | 用作kv3抑制剂的乙内酰脲衍生物 |
WO2013036232A2 (en) * | 2011-09-08 | 2013-03-14 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
ES2605388T3 (es) * | 2012-04-26 | 2017-03-14 | Ono Pharmaceutical Co., Ltd. | Compuesto inhibidor de Trk |
WO2013175211A1 (en) | 2012-05-22 | 2013-11-28 | Autifony Therapeutics Limited | Hydantoin derivatives as kv3 inhibitors |
BR112014028991A2 (pt) | 2012-05-22 | 2017-06-27 | Autifony Therapeutics Ltd | triazóis como inibidores de kv3 |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
WO2014015056A2 (en) * | 2012-07-17 | 2014-01-23 | Washington University | Anti-mucus drugs and uses therefor |
AU2013344886B2 (en) | 2012-11-13 | 2017-06-29 | Array Biopharma Inc. | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain |
WO2014078331A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9828360B2 (en) | 2012-11-13 | 2017-11-28 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078417A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9546156B2 (en) | 2012-11-13 | 2017-01-17 | Array Biopharma Inc. | N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors |
SG11201503728XA (en) | 2012-11-13 | 2015-06-29 | Array Biopharma Inc | N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078408A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078322A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
SG10201700808UA (en) | 2013-02-19 | 2017-02-27 | Ono Pharmaceutical Co | Trk-INHIBITING COMPOUND |
JP6276378B2 (ja) * | 2013-03-14 | 2018-02-07 | セルジーン クオンティセル リサーチ,インク. | ヒストンデメチラーゼ阻害剤 |
WO2014172639A1 (en) * | 2013-04-19 | 2014-10-23 | Ruga Corporation | Raf kinase inhibitors |
ITMI20132201A1 (it) * | 2013-12-23 | 2015-06-24 | Isagro Spa | Processo per la sintesi regioselettiva di pirazoli |
CN106866623A (zh) | 2014-04-08 | 2017-06-20 | 北大方正集团有限公司 | 多取代的吡啶化合物、制备方法、用途及药物组合物 |
NZ727418A (en) | 2014-05-15 | 2023-03-31 | Array Biopharma Inc | 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor |
CA3010561C (en) * | 2016-02-02 | 2024-04-16 | Basf Se | Catalytic hydrogenation process for preparing pyrazoles |
CN105646448B (zh) * | 2016-02-03 | 2019-03-01 | 沈阳药科大学 | 吡啶类化合物及其用途 |
CN108341813B (zh) * | 2017-01-24 | 2020-11-17 | 四川大学 | 取代的1-(异恶唑-3-基)-3-(3-氟-4-苯基)脲衍生物及其制备方法和用途 |
JP7335893B2 (ja) * | 2017-12-22 | 2023-08-30 | ラヴェンナ ファーマシューティカルズ,インコーポレイテッド | ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのクロメノピリジン誘導体 |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
FI3902547T3 (fi) | 2018-12-28 | 2023-12-05 | Deciphera Pharmaceuticals Llc | Csf1r-inhibiittoreita käytettäväksi syövän hoitamisessa |
WO2020181197A1 (en) * | 2019-03-06 | 2020-09-10 | University Of Maryland, Baltimore | Tetrameric protein scaffolds as nano-carriers of therapeutic peptides for treating cancer and other diseases |
FI3966207T3 (fi) | 2019-05-10 | 2023-11-30 | Deciphera Pharmaceuticals Llc | Autofagian fenyyliaminopyrimidiiniamidi-inhibiittoreita ja menetelmiä niiden käyttämiseksi |
ES2962852T3 (es) | 2019-05-10 | 2024-03-21 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de los mismos |
CN114258318A (zh) | 2019-06-17 | 2022-03-29 | 德西费拉制药有限责任公司 | 氨基嘧啶酰胺自噬抑制剂及其使用方法 |
KR20220038696A (ko) | 2019-07-19 | 2022-03-29 | 아나제네시스 바이오테크놀로지스 에스.에이.에스. | 폴리방향족 우레아 유도체 및 근육 질환 치료에서의 이들의 용도 |
WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
KR20220045189A (ko) | 2019-08-12 | 2022-04-12 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양을 치료하는 방법 |
EP4084779A1 (en) | 2019-12-30 | 2022-11-09 | Deciphera Pharmaceuticals, LLC | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
CA3163053A1 (en) | 2019-12-30 | 2021-07-08 | Michael D. Kaufman | Amorphous kinase inhibitor formulations and methods of use thereof |
BR112023009531A2 (pt) | 2020-11-18 | 2023-10-03 | Deciphera Pharmaceuticals Llc | Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos |
CN112830936B (zh) * | 2021-01-08 | 2022-01-28 | 广西师范大学 | 核黄素化合物、其制备方法及应用 |
EP4029501A1 (en) | 2021-01-19 | 2022-07-20 | Anagenesis Biotechnologies | Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1115350B (de) | 1959-04-17 | 1961-10-19 | Siemens Ag | Selbstschalter, insbesondere Leitungsschutz-schalter, mit einem aus einem Kniegelenk bestehenden Antriebsmechanismus fuer das Schaltorgan |
GB971307A (en) | 1961-03-02 | 1964-09-30 | Wellcome Found | 5-anilinopyrimidines |
GB1127875A (en) * | 1967-03-23 | 1968-09-18 | Parke Davis & Co | 4-(5-nitro-2-furyl) thiazolyl hydantoins and hydrouracils |
US3949002A (en) | 1970-11-13 | 1976-04-06 | Imperial Chemical Industries Limited | Process for producing sulfone containing thiophenols |
US3818024A (en) * | 1972-02-16 | 1974-06-18 | Velsicol Chemical Corp | Benzothiazol substituted thiadiazolidines |
CH565887A5 (ru) | 1972-08-22 | 1975-08-29 | Ciba Geigy Ag | |
US3939122A (en) * | 1973-04-11 | 1976-02-17 | Bayer Aktiengesellschaft | Process for the preparation of compounds which contain hydantoin rings |
FR2337554A1 (fr) | 1976-01-08 | 1977-08-05 | Buzas Andre | Nouveaux derives de la pyrazolidinedione |
US4093624A (en) * | 1977-01-31 | 1978-06-06 | Icn Pharmaceuticals, Inc. | 1,2,4-Thiadiazolidine-3,5-dione |
FR2396549A2 (fr) | 1977-07-06 | 1979-02-02 | Buzas Andre | Nouveaux derives de la pyrazolidinedione |
US4256758A (en) | 1979-06-11 | 1981-03-17 | Merck & Co., Inc. | 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase |
US4296237A (en) * | 1979-09-11 | 1981-10-20 | Merck & Co., Inc. | 4-(Pyridyl, piperazinyl and thiazolyl substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones |
US4298743A (en) | 1979-09-11 | 1981-11-03 | Merck & Co., Inc. | 4-(Substituted phenyl thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones |
US4432992A (en) | 1979-11-05 | 1984-02-21 | Merck & Co., Inc. | 4-[5(and 4)-Substituted-2-thienyl]-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase |
US4366189A (en) * | 1979-12-21 | 1982-12-28 | Ciba-Geigy Corporation | 4-Heterocyclyl-4'-vinylstilbenes |
JPS5915247A (ja) | 1982-07-16 | 1984-01-26 | Mitsubishi Paper Mills Ltd | 画像形成方法 |
JPS59177557A (ja) * | 1983-03-28 | 1984-10-08 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料 |
DE3406329A1 (de) | 1984-02-22 | 1985-08-22 | Merck Patent Gmbh, 6100 Darmstadt | Pyridone |
US4816454A (en) * | 1984-09-21 | 1989-03-28 | Cassella Aktiengesellschaft | 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use |
US5103014A (en) * | 1987-09-30 | 1992-04-07 | American Home Products Corporation | Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives |
AU606808B2 (en) | 1988-06-29 | 1991-02-14 | Otsuka Pharmaceutical Factory, Inc. | Arylcarboxamide substituted by alkylphosphonates, process for preparing the same and a pharmaceutical composition containing the same |
GB9012936D0 (en) | 1990-06-11 | 1990-08-01 | Fujisawa Pharmaceutical Co | Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
US5254715A (en) | 1990-11-07 | 1993-10-19 | Warner-Lambert Company | Aminosulfonyl carbamates |
KR0133550B1 (ko) * | 1991-01-21 | 1998-04-23 | 요시또시 가즈오 | 3-벤질리덴-1-카르바모일-2-피롤리돈 유사체 |
US5162360A (en) | 1991-06-24 | 1992-11-10 | Warner-Lambert Company | 2-heteroatom containing urea and thiourea ACAT inhibitors |
DE4302702A1 (de) | 1993-02-01 | 1994-08-04 | Bayer Ag | Arylaminosulfonylharnstoffe |
WO1994021617A1 (en) | 1993-03-19 | 1994-09-29 | Dowelanco | A process for preparing halogenated isothiazoles |
WO1994022872A1 (en) | 1993-03-30 | 1994-10-13 | Yoshitomi Pharmaceutical Industries, Ltd. | Cell adhesion inhibitor and thienotriazolodiazepine compound |
WO1994024095A1 (en) | 1993-04-16 | 1994-10-27 | Abbott Laboratories | Immunosuppressive agents |
CA2123728A1 (en) | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Urea derivatives and their use as acat inhibitors |
DE4337847A1 (de) | 1993-11-05 | 1995-05-11 | Bayer Ag | Substituierte Phenylaminosulfonylharnstoffe |
AU1108395A (en) | 1993-12-07 | 1995-06-27 | Smithkline Beecham Plc | Heterocyclic biphenylylamides useful as 5ht1d antagonists |
DE4343831A1 (de) | 1993-12-22 | 1995-06-29 | Magyar Tudomanyos Akademia | Substituierte Sulfonylharnstoffe |
FR2715155B1 (fr) * | 1994-01-19 | 1996-07-26 | Mayoly Spindler | Inhibiteurs de la monoamine oxydase B et leurs procédés de préparation. |
DE4414840A1 (de) | 1994-04-28 | 1995-11-02 | Bayer Ag | Substituierte Phenylaminosulfonylharnstoffe |
MX9606510A (es) | 1994-06-15 | 1997-03-29 | Otsuka Pharma Co Ltd | Derivados benzoheterociclicos. |
WO1996016046A2 (en) | 1994-11-24 | 1996-05-30 | F. Hoffmann-La Roche Ag | Novel benzyl pyrimidines |
US5494925A (en) | 1994-12-02 | 1996-02-27 | Sterling Winthrop Inc. | 2-heterocyclyloxymethyl and 2-heterocyclylthiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof |
HUT77650A (hu) | 1994-12-22 | 1998-07-28 | Smithkline Beecham P.L.C. | Spiro{(furo[2,3-f]indol-, furo[2,3-g]kinolin- és furo[2,3-h]benzazepin)-3,4'-piperidin}-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények |
EP0739884B1 (en) | 1995-04-24 | 2003-08-13 | Semiconductor Energy Laboratory Co., Ltd. | Liquid crystal compound and liquid crystal composition containing the same |
JPH09221476A (ja) | 1995-12-15 | 1997-08-26 | Otsuka Pharmaceut Co Ltd | 医薬組成物 |
GB9605945D0 (en) | 1996-03-21 | 1996-05-22 | Smithkline Beecham Plc | Novel compounds |
CN1515248A (zh) * | 1996-04-23 | 2004-07-28 | ��̩��˹ҩ��ɷ�����˾ | 用作肌苷-5'-一磷酸脱氢酶抑制剂的脲衍生物 |
JPH107804A (ja) | 1996-06-25 | 1998-01-13 | Japan Synthetic Rubber Co Ltd | 熱硬化性樹脂組成物 |
GB9623833D0 (en) | 1996-11-16 | 1997-01-08 | Zeneca Ltd | Chemical compound |
US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
EP0867435B1 (en) | 1997-03-27 | 2003-01-08 | Great Lakes Chemical (Europe) GmbH | 2-(2'Hydroxyphenyl) benzotriazoles and their use as light stabilizers for organic polymers |
ATE277612T1 (de) | 1997-05-23 | 2004-10-15 | Bayer Ag | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen |
US6294573B1 (en) | 1997-08-06 | 2001-09-25 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
US6235786B1 (en) * | 1997-08-06 | 2001-05-22 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
ATE229329T1 (de) | 1997-09-23 | 2002-12-15 | Astrazeneca Ab | Amide derivativen zur behandlung von durch cytokinen vermittelten krankheiten |
IT1295933B1 (it) | 1997-10-30 | 1999-05-28 | Great Lakes Chemical Italia | 2-(2'-idrossifenil)benzotriazoli e procedimento per la loro preparazione |
AU1367599A (en) | 1997-11-03 | 1999-05-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
IL136768A0 (en) | 1997-12-22 | 2001-06-14 | Bayer Ag | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS |
UA71904C2 (en) * | 1997-12-22 | 2005-01-17 | Compounds and methods of treating by inhibiting raf kinase using heterocyclic substituted urea derivatives | |
TR200002617T2 (tr) | 1997-12-22 | 2000-11-21 | Bayer Corporation | Aril ve heteroaril sübstitüentli heterosiklik üreler kullanılarak RAF kinazın inhibe edilmesi |
IL136738A0 (en) | 1997-12-22 | 2001-06-14 | Bayer Ag | Inhibition of p38 kinase activity using substituted heterocyclic ureas |
US6887893B1 (en) | 1997-12-24 | 2005-05-03 | Sankyo Company, Limited | Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia |
SI0928790T1 (en) * | 1998-01-02 | 2003-06-30 | F. Hoffmann-La Roche Ag | Thiazole derivatives |
ATE234099T1 (de) | 1998-04-24 | 2003-03-15 | Leuven K U Res & Dev | Immununterdrückende effekte von 8 substituierten xanthinderivaten |
US6197599B1 (en) * | 1998-07-30 | 2001-03-06 | Guorong Chin | Method to detect proteins |
GB9823873D0 (en) * | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
JP2000275886A (ja) | 1999-03-23 | 2000-10-06 | Konica Corp | 電子写真感光体、それを用いたプロセスカートリッジ及び画像形成装置 |
US6410254B1 (en) * | 1999-05-18 | 2002-06-25 | Cytokinetics | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
US6525046B1 (en) * | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
US6500628B1 (en) | 2000-05-25 | 2002-12-31 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding human kinase and phosphatase homologues and uses therefor |
US6645990B2 (en) | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
KR100589032B1 (ko) * | 2000-10-20 | 2006-06-14 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
WO2002066442A1 (en) * | 2001-02-15 | 2002-08-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents |
ES2360205T3 (es) | 2001-03-02 | 2011-06-01 | Agennix Ag | Sistema de ensayo de tres híbridos. |
DE60214532T2 (de) * | 2001-03-23 | 2007-04-12 | Merck Sharp & Dohme Ltd., Hoddesdon | Imidazopyrimidin-derivate als liganden für gaba-rezeptoren |
EP1281399A3 (en) | 2001-08-01 | 2004-02-11 | Warner-Lambert Company | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production |
CA2458029A1 (en) * | 2001-09-13 | 2003-03-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating cytokine mediated diseases |
US20040023961A1 (en) | 2002-02-11 | 2004-02-05 | Bayer Corporation | Aryl ureas with raf kinase and angiogenisis inhibiting activity |
JP4636486B2 (ja) * | 2002-02-11 | 2011-02-23 | バイエル、ファーマシューテイカルズ、コーポレイション | 脈管形成阻害活性を有するアリール尿素 |
CA2473634C (en) * | 2002-02-25 | 2011-11-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases |
AR037647A1 (es) * | 2002-05-29 | 2004-12-01 | Novartis Ag | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |
JP2005538975A (ja) | 2002-07-03 | 2005-12-22 | アステックス テクノロジー リミテッド | p38MAPキナーゼ阻害薬としての3−(ヘテロ)アリールメトキシピリジン類およびそれらの類縁体 |
US20040138216A1 (en) | 2002-12-23 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for the preparation of an essentially pure polymorph of an n-pyrazolyl-n'-naphthyl-urea |
US7144911B2 (en) * | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
US20080045706A1 (en) * | 2002-12-31 | 2008-02-21 | Flynn Daniel L | Anti-inflammatory medicaments |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US20040171075A1 (en) | 2002-12-31 | 2004-09-02 | Flynn Daniel L | Modulation of protein functionalities |
UY28213A1 (es) * | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
CA2516627A1 (en) * | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | Substituted pyridine derivatives useful in the treatment of cancer and other disorders |
WO2004113352A1 (en) | 2003-06-19 | 2004-12-29 | Amedis Pharmaceuticals Ltd. | Silylated heterocyclylurea derivatives as cytokine-inhibitors |
WO2005002673A1 (en) | 2003-07-03 | 2005-01-13 | Astex Therapeutics Limited | Raf kinase inhibitors |
US20050148605A1 (en) * | 2003-11-13 | 2005-07-07 | Ambit Biosciences Corporation | Amide derivatives as ABL modulators |
US20080220497A1 (en) * | 2003-12-24 | 2008-09-11 | Flynn Daniel L | Modulation of protein functionalities |
US20070191336A1 (en) * | 2003-12-24 | 2007-08-16 | Flynn Daniel L | Anti-inflammatory medicaments |
US20090312349A1 (en) * | 2004-12-23 | 2009-12-17 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
EP2942349A1 (en) * | 2004-12-23 | 2015-11-11 | Deciphera Pharmaceuticals, LLC | Enzyme modulators and treatments |
US7622583B2 (en) * | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
TW200804349A (en) * | 2005-12-23 | 2008-01-16 | Kalypsys Inc | Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases |
US7790756B2 (en) * | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
US20080248487A1 (en) * | 2007-04-09 | 2008-10-09 | Flynn Daniel L | Modulation of protein functionalities |
US20080248548A1 (en) * | 2007-04-09 | 2008-10-09 | Flynn Daniel L | Modulation of protein functionalities |
CN101878031A (zh) | 2007-04-20 | 2010-11-03 | 迪赛孚尔制药有限公司 | 用于治疗骨髓增生性疾病和其他增生性疾病的激酶抑制剂 |
-
2008
- 2008-04-18 CN CN2008800085252A patent/CN101878031A/zh active Pending
- 2008-04-18 MX MX2009009066A patent/MX2009009066A/es not_active Application Discontinuation
- 2008-04-18 WO PCT/US2008/060833 patent/WO2008131227A1/en active Application Filing
- 2008-04-18 AU AU2008251723A patent/AU2008251723A1/en not_active Abandoned
- 2008-04-18 US US12/105,408 patent/US8143293B2/en not_active Expired - Fee Related
- 2008-04-18 RU RU2009142851/15A patent/RU2009142851A/ru not_active Application Discontinuation
- 2008-04-18 CA CA002684949A patent/CA2684949A1/en not_active Abandoned
- 2008-04-18 EP EP08746333A patent/EP2148677A4/en not_active Withdrawn
- 2008-04-18 CA CA002678639A patent/CA2678639A1/en not_active Abandoned
- 2008-04-18 JP JP2010504293A patent/JP2010524974A/ja active Pending
- 2008-04-18 KR KR1020097017379A patent/KR20100014811A/ko not_active Application Discontinuation
- 2008-04-18 WO PCT/US2008/060855 patent/WO2008140895A1/en active Application Filing
- 2008-04-18 EP EP08746294A patent/EP2146717A4/en not_active Withdrawn
- 2008-04-18 CA CA002684666A patent/CA2684666A1/en not_active Abandoned
- 2008-04-18 EP EP12153098A patent/EP2481736A1/en not_active Withdrawn
- 2008-04-18 CA CA002684950A patent/CA2684950A1/en active Pending
- 2008-04-18 EP EP08746279A patent/EP2146716A4/en not_active Withdrawn
- 2008-04-18 US US12/105,302 patent/US20080269267A1/en not_active Abandoned
- 2008-04-18 EP EP08746306A patent/EP2146718A4/en not_active Withdrawn
- 2008-04-18 SG SG2012053559A patent/SG183054A1/en unknown
- 2008-04-18 US US12/105,350 patent/US20080269254A1/en not_active Abandoned
- 2008-04-18 US US12/105,376 patent/US20080261961A1/en not_active Abandoned
- 2008-04-18 BR BRPI0807717-7A2A patent/BRPI0807717A2/pt not_active IP Right Cessation
- 2008-04-18 JP JP2010504274A patent/JP2010524970A/ja active Pending
- 2008-04-18 KR KR1020097024209A patent/KR20100017184A/ko not_active Application Discontinuation
- 2008-04-18 BR BRPI0810094-2A2A patent/BRPI0810094A2/pt not_active IP Right Cessation
- 2008-04-18 EA EA200970700A patent/EA200970700A1/ru unknown
- 2008-04-18 WO PCT/US2008/060867 patent/WO2008131253A1/en active Application Filing
- 2008-04-18 MX MX2009011343A patent/MX2009011343A/es not_active Application Discontinuation
- 2008-04-18 AU AU2008242720A patent/AU2008242720A1/en not_active Abandoned
- 2008-04-18 AU AU2008242767A patent/AU2008242767A1/en not_active Abandoned
- 2008-04-18 CN CN200880020714A patent/CN101801383A/zh active Pending
- 2008-04-18 AU AU2008242697A patent/AU2008242697A1/en not_active Abandoned
- 2008-04-18 WO PCT/US2008/060896 patent/WO2008131276A1/en active Application Filing
-
2009
- 2009-10-20 IL IL201650A patent/IL201650A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200970700A1 (ru) | Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний | |
EA201170627A1 (ru) | Циклопропанамиды и аналоги, проявляющие противораковые и антипролиферативные активности | |
WO2013036232A3 (en) | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases | |
Elias et al. | Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases | |
NZ593114A (en) | Compounds comprising benzimidazolyl, pyrimidinyl, and pyridinyl moieties which are useful as protein kinase inhibitors | |
EA201391470A1 (ru) | Замещенные соли 2,3-дигидроимидазо[1,2-c]хиназолина | |
CY1118730T1 (el) | Παραγωγα πυριδινης ως αναστολεις της αναδιαταχθεισας κατα την διαρκεια διαλοιμωξης (ret) κινασης | |
JP2017511311A5 (ru) | ||
RU2015128606A (ru) | Производные азаиндола в качестве ингибиторов протеинкиназ | |
JP2010501572A5 (ru) | ||
NZ576425A (en) | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors | |
RU2014125230A (ru) | Пиридонамиды и их аналоги, демонстрирующие противораковую и антипролиферативную активность | |
RU2017131430A (ru) | Способ лечения рака, ассоциированного с мутацией ras | |
RU2012151012A (ru) | Циклопропиловые дикарбоксамиды и аналоги, обладающие противораковым и антипролиферативным действием | |
Lim et al. | CDK4/6 inhibitors: promising opportunities beyond breast cancer | |
BR122012012032B8 (pt) | usos de inibidores de cinase úteis para preparação de composições farmacêuticas utilizáveis no tratamento de doenças proliferativas | |
JP2008513366A5 (ru) | ||
TN2017000486A1 (en) | Polycyclic amide derivatives as cdk9 inhibitors | |
EA201492004A1 (ru) | Органические композиции для лечения kras-ассоциированных заболеваний | |
JP2017514806A5 (ru) | ||
Zhu et al. | Design, synthesis, and pharmacological evaluation of novel multisubstituted pyridin-3-amine derivatives as multitargeted protein kinase inhibitors for the treatment of non-small cell lung cancer | |
Newton et al. | The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity | |
JP2018536682A5 (ru) | ||
Schram et al. | Abstract PR02: Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers | |
RU2017105817A (ru) | Комбинированная терапия |